FDA Approves First Treatment for MCT8 Deficiency

A treatment for the peripheral thyroid phenotype

The FDA’s September 28, 2026, decision addresses a specific part of monocarboxylate transporter 8 (MCT8) deficiency: peripheral thyrotoxicosis. The rare X-linked disorder, also known as Allan-Herndon-Dudley syndrome, results from pathogenic variants in the gene responsible for the MCT8 transporter, which helps move thyroid hormone into cells and is especially important for thyroid hormone access to the brain.

The disorder creates two closely linked but different problems. Impaired thyroid hormone transport in the brain can lead to severe neurodevelopmental and motor disability, while high circulating T3 exposes peripheral tissues to excessive thyroid hormone activity. Typical laboratory findings include elevated T3, low thyroxine (T4), and a thyroid-stimulating hormone (TSH) level that may be normal or mildly elevated.

This peripheral excess can have meaningful clinical effects. Patients may develop tachycardia, elevated systolic blood pressure, increased energy expenditure, low body weight and muscle wasting. These problems can add cardiovascular and nutritional stress to a condition already associated with profound motor impairment and substantial dependence on caregivers.

Tiratricol, also known as triiodothyroacetic acid (Triac), is a thyroid hormone analog. Unlike T3, it can enter peripheral tissues without depending on functional MCT8. It also lowers circulating T3 through feedback on the hypothalamic-pituitary-thyroid axis. The treatment goal is therefore focused on the peripheral phenotype: reduce excess T3 and its effects without further limiting thyroid hormone availability in the brain.

What the clinical evidence showed

Published evidence supporting this approach includes an international, open-label, single-arm phase 2 trial of 46 children and adults with MCT8 deficiency. Participants received tiratricol and were followed for 12 months. There was no placebo or active-control group.

Mean serum T3 fell from 4.97 nmol/L at baseline to 1.82 nmol/L after 12 months, a mean reduction of 3.15 nmol/L. The 95% confidence interval for the reduction was 2.68 to 3.62 nmol/L, with a p-value below 0.0001.

Several peripheral clinical measures moved in the same direction. Resting heart rate declined by a mean of 9 beats per minute, systolic blood pressure by 18 mm Hg, and weight-for-age z score increased by 0.27. These results are consistent with reduced peripheral thyroid hormone activity, although the uncontrolled design limits causal certainty for clinical outcomes beyond the large biochemical change.

The trial’s age range was broad, reflecting the rarity of the condition, but that breadth does not substitute for adequately powered subgroup comparisons. The FDA decision establishes the approved indication and regulatory assessment; the phase 2 trial provides published context for how lowering T3 may translate into cardiovascular and metabolic changes.

How management may change

Before an approved disease-specific therapy, management of peripheral thyrotoxicosis was largely supportive and fragmented. Clinicians could address tachycardia, blood pressure, feeding difficulty and poor weight gain separately, but those measures did not directly correct the abnormal thyroid hormone state driving multiple manifestations.

Tiratricol introduces a treatment aimed at that shared mechanism. Heart rate and blood pressure remain clinically relevant endpoints because persistent tachycardia and elevated systolic pressure may signal ongoing peripheral thyroid hormone exposure. Serial measurements can help clinicians assess whether biochemical improvement is accompanied by a meaningful physiologic response, while also identifying cardiovascular findings that require separate evaluation.

Weight and nutritional status require similarly careful interpretation. Reduced hypermetabolic demand may support weight gain, but children and adults with MCT8 deficiency can also have dysphagia, altered muscle mass, immobility and feeding dependence. A change in body weight therefore cannot be attributed automatically to thyroid control. Growth trajectory, nutritional intake and body composition remain important alongside thyroid testing.

The indication should also sharpen communication with families. Treating peripheral thyrotoxicosis is not equivalent to reversing established neurologic injury. MCT8 deficiency limits thyroid hormone entry into the developing brain, and the available peripheral outcomes do not demonstrate recovery of motor or cognitive function. Expectations should distinguish improvement in biochemical, cardiovascular or metabolic burden from improvement in the core neurodevelopmental phenotype.

Implementation will require coordinated care. Endocrinology teams may follow thyroid function and peripheral response, while cardiology, nutrition, neurology, rehabilitation and primary care continue to manage the disorder’s broader consequences. Treatment does not remove the need to evaluate other causes of tachycardia, hypertension or poor growth.

Important evidence gaps

The principal published trial was small, open label and uncontrolled. MCT8 deficiency is exceptionally rare, making conventional large randomized trials difficult, but the absence of a comparator leaves the clinical outcomes vulnerable to maturation, regression to the mean, concurrent care and measurement variability. The findings support an effect on serum T3; they provide less definitive evidence about long-term cardiovascular events, survival or functional status.

Generalizability also remains uncertain. A cohort spanning young children through adults cannot reliably determine whether treatment effects differ by age, genotype, disease severity or duration of peripheral thyrotoxicosis. Longer follow-up is needed to clarify durability, growth and body-composition outcomes, cardiovascular consequences, and uncommon adverse effects.

The regulatory indication is specifically peripheral thyrotoxicosis. Evidence should not be extended to prevention or reversal of neurodevelopmental disability without separate data. Whether very early treatment alters neurologic development is a distinct question from whether tiratricol lowers T3 and reduces peripheral thyroid hormone effects.

Questions clinicians ask

Which manifestations does the FDA indication address?

It addresses peripheral thyrotoxicosis associated with MCT8 deficiency, including the excess-T3 state underlying tachycardia, elevated systolic blood pressure, hypermetabolism, low weight and muscle wasting. It should not be interpreted as an indication for established motor, cognitive or other neurologic manifestations.

Can tiratricol replace treatment for tachycardia or hypertension?

The evidence supports assessing whether lowering T3 reduces heart rate and blood pressure, but it does not show that every cardiovascular abnormality will resolve. Persistent or severe findings still warrant evaluation for other causes and management according to their clinical significance; the published trial did not compare tiratricol with cardiovascular drugs.

What should be followed after treatment begins?

The evidence supports monitoring thyroid biochemistry together with resting heart rate, blood pressure, weight and broader nutritional status. Because MCT8 deficiency involves severe neurologic and feeding-related morbidity, multidisciplinary follow-up remains necessary even when serum T3 and peripheral physiologic measures improve.

Does approval mean neurologic benefit has been established?

No. The approval concerns peripheral thyrotoxicosis, and the reported trial outcomes primarily establish biochemical improvement with accompanying cardiovascular and weight changes. Those findings do not demonstrate reversal of established neurodevelopmental disability, nor do they establish that later treatment can restore thyroid hormone action in the brain.

References

1. FDA Approves First Treatment for MCT8 Deficiency — U.S. Food and Drug Administration, 2026 2. Effectiveness and Safety of the Tri-Iodothyronine Analogue Triac in Children and Adults With MCT8 Deficiency: An International, Single-Arm, Open-Label, Phase 2 Trial30155-X) — The Lancet Diabetes & Endocrinology, 2019 3. Triac in MCT8 Deficiency — ClinicalTrials.gov, 2014